Tauseef Butt obtained his BS/MS from University of Dundee, Dundee, Scotland. He has a PhD in Mol Biology from the University of Glasgow, Glasgow Scotland. UK, He was a Staff Fellow at the National Institutes of Health, Bethesda, MD, before joining SmithKline (now GSK) Pharmaceuticals. His group was responsible for several therapeutic areas during his 14 years in the SmithKline organization, where he led one of the first ubiquitin drug discovery efforts in the industry. Tauseef Butt was an Adjunct Professor of Biochemistry and Biophysics at University of Pennsylvania, Philadelphia, from 1989-2000. He is an Adjunct Professor in Biomedical Engineering at Drexel University, Philadelphia PA. He is active in a number of national and regional biotechnology organizations. Tauseef But is a co- founder of Progenra, Inc. He has raised over $130 million capital over last few years. Progenra is dedicated to discovery and development of innovative medicines by exploiting ubiquitin proteasome system, molecular glues and PROTAC drugs. Currently he is the CEO of Progenra. Dr. Butt is also the co-founder of Abzyme Inc. a biotech company exploiting novel molecular evolutionary platform to generate novel therapeutic antibodies.